safranal has been researched along with Diabetes Mellitus, Type 2 in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Akagawa, M; Ishii, M; Ishii, T; Kai, K; Maeda, A | 1 |
Hazman, Ö; Ovalı, S | 1 |
Bozkurt, MF; Hazman, Ö | 1 |
3 other study(ies) available for safranal and Diabetes Mellitus, Type 2
Article | Year |
---|---|
Safranal, a novel protein tyrosine phosphatase 1B inhibitor, activates insulin signaling in C2C12 myotubes and improves glucose tolerance in diabetic KK-Ay mice.
Topics: Animals; Crocus; Cyclohexenes; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred Strains; Muscle Fibers, Skeletal; Myoblasts; Plant Extracts; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Signal Transduction; Terpenes | 2014 |
Investigation of the anti-inflammatory effects of safranal on high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model.
Topics: Animals; Anti-Inflammatory Agents; Blood Glucose; Cyclohexenes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Inflammation; Insulin Resistance; Interferon-gamma; Interleukin-1beta; Interleukin-6; Male; Obesity; Oxidative Stress; Pancreas; Rats; Rats, Wistar; Streptozocin; Terpenes; Tumor Necrosis Factor-alpha; Weight Gain | 2015 |
Anti-inflammatory and Antioxidative Activities of Safranal in the Reduction of Renal Dysfunction and Damage that Occur in Diabetic Nephropathy.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cyclohexenes; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Kidney; Male; Rats; Rats, Wistar; Terpenes | 2015 |